Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Vasc Interv Radiol ; 35(5): 659-663, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38355039

RESUMEN

This retrospective case series assessed the early effectiveness of combined spontaneous portosystemic shunt (SPSS) embolization and preemptive transjugular intrahepatic portosystemic shunt (TIPS) creation for alleviation of medically refractory hepatic encephalopathy (HE) and prevention of portal hypertension complications in patients with liver cirrhosis. Eight patients with liver cirrhosis (5 men and 3 women; mean age, 61 years [SD ± 10]) and HE (overt [West-Haven Grade 2-4], n = 7; covert [West-Haven Grade 1], n = 1) refractory to lactulose and rifaximin therapy who underwent concurrent or staged SPSS embolization and TIPS creation between 2018 and 2022 were included in this study. The primary outcomes were 3-month improvement in HE and postprocedural HE-related hospitalizations. HE improvement was achieved in 7 (87.5%) of 8 cases. Among all patients, there was 1 HE-related hospitalization within 90 days that responded to repeat embolization with no further admissions. No patients developed new ascites, variceal hemorrhage, or other portal hypertension complications within 3 months.


Asunto(s)
Embolización Terapéutica , Encefalopatía Hepática , Cirrosis Hepática , Derivación Portosistémica Intrahepática Transyugular , Humanos , Encefalopatía Hepática/etiología , Encefalopatía Hepática/terapia , Persona de Mediana Edad , Masculino , Embolización Terapéutica/efectos adversos , Femenino , Derivación Portosistémica Intrahepática Transyugular/efectos adversos , Estudios Retrospectivos , Resultado del Tratamiento , Anciano , Cirrosis Hepática/complicaciones , Factores de Tiempo , Hipertensión Portal/fisiopatología , Hipertensión Portal/etiología , Hipertensión Portal/terapia , Presión Portal
2.
J Vasc Interv Radiol ; 35(1): 80-85, 2024 01.
Artículo en Inglés | MEDLINE | ID: mdl-37741437

RESUMEN

This retrospective analysis of the feasibility and safety of percutaneous renal stone removal using single-use flexible ureteroscopes was conducted at 3 academic centers. Twelve patients (58% men) underwent 14 percutaneous renal stone removal procedures between December 2021 and March 2023. All patients experienced symptom improvement and resolution of obstruction after stone removal. The procedural success rate was 92%. Only 1 patient required an additional stone removal procedure. No major adverse events occurred during or after the procedures. The percutaneous nephrostomy removal rate was 92%, with a median tube removal time of 5 weeks. The median procedural and pulsed fluoroscopy times were 106.5 and 16.3 minutes, respectively. Preliminary findings demonstrated that percutaneous renal stone removal using single-use endoscopes by interventional radiologists is feasible and safe.


Asunto(s)
Cálculos Renales , Nefrostomía Percutánea , Masculino , Humanos , Femenino , Estudios Retrospectivos , Radiología Intervencionista , Cálculos Renales/diagnóstico por imagen , Cálculos Renales/cirugía , Riñón , Nefrostomía Percutánea/efectos adversos , Nefrostomía Percutánea/métodos , Resultado del Tratamiento
5.
Semin Intervent Radiol ; 39(3): 271-274, 2022 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-36062234

RESUMEN

Pericardial effusions can occur from multiple different etiologies. Although often incidentally noted or clinically silent, pericardial effusions may cause significant hemodynamic compromise. In some of these patients, pericardiocentesis may be temporizing only and either repeat procedures or placement of pericardial drains may be preferable. While cardiologists typically perform pericardial drain placement, it is a procedure that may also be performed by interventional radiologists. This article describes for the interventional radiologist the indications and placement technique, as well as potential complications occurring from pericardial drain placement.

6.
Semin Intervent Radiol ; 37(1): 74-84, 2020 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-32139973

RESUMEN

Pyonephrosis is gross accumulation of pus within an obstructed renal collecting system that, if left untreated, can lead to potentially fatal septic shock. Treatment requires urgent decompression coupled with systemic antibiotics. Percutaneous nephrostomy (PCN) placement, first described in 1976 for the treatment of pyonephrosis, is now widely utilized for emergent decompression in these patients. When performed by an experienced interventional radiologist, PCN is a safe procedure with technical success rates of over 96 to 99%. This article will address the clinical presentation of pyonephrosis, and will discuss the indications, technique, complications, and outcomes of emergent PCN placement. Additionally, the expanded indications for PCN placement in nonemergent scenarios will also be described.

8.
J Surg Oncol ; 117(7): 1493-1499, 2018 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-29484654

RESUMEN

BACKGROUND AND OBJECTIVES: Ablation is a common treatment modality for malignant primary liver tumors(PLTs), outcomes following laparoscopic (LA) versus open ablation (OA) are ill-defined. This project compares peri-procedural outcomes of LA versus OA for PLTs. MATERIALS AND METHODS: Patients with PLTs undergoing radiofrequency ablation were queried from ACS NSQIP Database (2005-2013) using CPT codes. Patients undergoing percutaneous ablation or hepatic resection were excluded. Multivariable logistic regression analyses determined the association of ablation approach with 30-day morbidity and mortality. RESULTS: Of 5747 with PLTs, 655 (11.4%) ablations were identified: 177 (27.0%) underwent OA, 478 (73.0%) underwent LA. Patients undergoing LA had lower mortality (1.9% vs 5.1%, P = 0.026), lower minor morbidity (2.3% vs 5.7%, P = 0.031), and lower major morbidity (4.2% vs 17.0%, P < 0.001). Adjusting for demographics, disease-specific variables (preoperative ascites, total bilirubin, platelet count, albumin, and INR), 30-day mortality (OR 3.85, 95%CI: 1.38-10.80, P = 0.010), minor morbidity (OR 2.98, 95%CI: 1.16-7.67, P = 0.024), and major morbidity (OR 4.59 95%CI: 2.41-8.76, P < 0.001) were statistically lower in LA. OA demonstrated increased length of stay(LOS) (5 vs 2 days, P < 0.001), and longer operative time (152 vs 112 min, P < 0.001). CONCLUSION: LA offers decreased peri-procedural morbidity, mortality, and reduced LOS. LA should be the preferred method for hepatic ablation.


Asunto(s)
Ablación por Catéter/mortalidad , Laparoscopía/mortalidad , Neoplasias Hepáticas/cirugía , Atención Perioperativa , Complicaciones Posoperatorias , Anciano , Femenino , Estudios de Seguimiento , Humanos , Tiempo de Internación , Neoplasias Hepáticas/patología , Masculino , Persona de Mediana Edad , Tempo Operativo , Estudios Retrospectivos , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...